Immunartes, Chicago, USA
www.immunartes.com

Immunartes is developing a monoclonal antibody to prevent infections caused by Staphylococcus aureus. The antibody is designed to neutralize the pathogen’s immune-evasive mechanisms, thereby enhancing its clearance by the body’s natural immune cells. If successful, the preventative could be a promising solution for providing immediate protection to high-risk populations, preventing colonization, and reducing the likelihood of recurrent disease.

S. aureus is a leading cause of life-threatening bloodstream infections, such as sepsis and endocarditis, and is responsible for more than 1 million deaths annually. Methicillin-resistant S. aureus (MRSA) is a primary contributor to deaths related to antimicrobial resistance.

Current Development Stage: Hit-to-Lead

CARB-X Investment: Initial investment of US$729k

Initial CARB-X Investment Date: January 23, 2025